Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 17 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-46.45 Insider Own45.79% Shs Outstand0.89M Perf Week0.45%
Market Cap10.67M Forward P/E- EPS next Y- Insider Trans0.29% Shs Float0.86M Perf Month-1.53%
Income-19.19M PEG- EPS next Q- Inst Own20.36% Short Float2.19% Perf Quarter41.81%
Sales0.12M P/S88.88 EPS this Y- Inst Trans-14.52% Short Ratio0.75 Perf Half Y-16.57%
Book/sh0.90 P/B7.54 EPS next Y- ROA-312.93% Short Interest0.02M Perf Year-90.03%
Cash/sh1.88 P/C3.59 EPS next 5Y- ROE-759.09% 52W Range4.43 - 68.46 Perf YTD-27.48%
Dividend Est.- P/FCF- EPS past 5Y48.34% ROI-721.01% 52W High-90.14% Beta0.92
Dividend TTM- Quick Ratio1.52 Sales past 5Y14.71% Gross Margin7.66% 52W Low52.30% ATR (14)0.63
Dividend Ex-Date- Current Ratio1.52 EPS Y/Y TTM50.61% Oper. Margin-18526.61% RSI (14)54.31 Volatility11.29% 9.27%
Employees40 Debt/Eq0.07 Sales Y/Y TTM-84.97% Profit Margin-15472.58% Recom1.00 Target Price1470.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q85.95% Payout- Rel Volume17.08 Prev Close6.00
Sales Surprise- EPS Surprise- Sales Q/Q-81.09% Earnings- Avg Volume25.03K Price6.75
SMA205.60% SMA508.95% SMA200-23.44% Trades Volume337,062 Change12.50%
Date Action Analyst Rating Change Price Target Change
Sep-23-20Downgrade BTIG Research Buy → Neutral
Sep-04-18Initiated Ladenburg Thalmann Buy $22
Jul-17-24 08:00AM
Jun-06-24 08:30AM
May-16-24 06:52AM
May-15-24 06:00PM
Apr-02-24 01:52PM
08:30AM Loading…
Mar-27-24 08:30AM
Feb-21-24 08:00AM
Feb-15-24 08:00AM
Feb-12-24 11:03AM
Feb-07-24 08:00AM
Dec-04-23 08:00AM
Nov-13-23 08:00AM
Oct-31-23 09:00AM
Oct-26-23 09:30AM
08:08AM Loading…
Oct-06-23 08:08AM
Sep-28-23 09:00PM
Sep-27-23 08:00AM
Sep-26-23 08:00AM
Sep-22-23 04:30PM
Aug-14-23 08:10AM
Jun-01-23 08:00AM
May-15-23 04:45PM
Apr-25-23 08:00AM
Apr-12-23 08:00AM
Apr-03-23 08:30AM
Mar-23-23 08:00AM
Mar-21-23 08:30AM
08:00AM Loading…
Mar-09-23 08:00AM
Jan-26-23 06:06PM
Jan-09-23 08:00AM
Nov-29-22 05:43PM
Nov-28-22 08:00AM
Nov-16-22 05:38AM
Nov-14-22 08:30AM
Nov-10-22 09:00AM
Nov-03-22 06:16AM
Aug-15-22 08:10AM
Aug-08-22 11:00AM
Jul-29-22 07:00AM
Jul-21-22 08:21AM
May-25-22 08:00AM
May-16-22 08:15AM
Apr-25-22 08:00AM
Mar-31-22 09:15AM
Mar-09-22 09:00AM
Feb-24-22 08:00AM
Feb-11-22 11:24AM
Jan-28-22 07:57AM
Jan-27-22 04:15PM
Jan-26-22 11:18AM
Jan-04-22 08:00AM
Nov-10-21 08:00AM
Nov-09-21 08:00AM
Nov-08-21 08:15AM
Nov-04-21 08:00AM
Nov-01-21 08:00AM
Sep-17-21 08:00AM
Sep-15-21 08:00AM
Aug-16-21 08:15AM
Jul-21-21 07:45AM
Jun-30-21 08:00AM
Jun-08-21 07:57AM
May-19-21 08:00AM
May-17-21 08:15AM
Apr-21-21 08:00AM
Mar-16-21 08:05AM
Mar-11-21 08:00AM
Feb-23-21 07:25AM
Feb-22-21 08:30AM
Feb-19-21 12:20PM
Jan-07-21 08:19AM
Jan-06-21 08:43AM
Jan-05-21 08:00AM
Nov-13-20 08:05AM
Oct-29-20 11:15AM
Oct-26-20 07:55AM
Oct-12-20 08:53AM
Sep-23-20 10:34AM
Sep-22-20 08:40AM
Sep-17-20 08:00AM
Aug-27-20 08:00AM
Aug-14-20 09:45AM
Aug-05-20 12:30PM
Jul-16-20 11:30AM
Jul-07-20 08:37AM
Jun-09-20 08:00AM
May-14-20 10:05AM
May-13-20 05:02PM
Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington's disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRIEDBERG ALBERTDirectorMay 30 '24Buy5.208614,473562,415May 31 04:31 PM
FRIEDBERG ALBERTDirectorMay 29 '24Buy4.959574,737561,554May 31 04:31 PM
FRIEDBERG ALBERTDirectorApr 19 '24Buy4.732821,334560,597Apr 22 04:33 PM
Van Strydonck, Gerald E.DirectorDec 26 '23Sale0.723,1492,2670Dec 28 04:31 PM
Van Strydonck, Gerald E.DirectorDec 08 '23Sale0.671,3348943,149Dec 12 04:31 PM
Zauderer MauricePresident and CEOOct 04 '23Buy0.975,0004,86522,116Oct 05 04:31 PM
FRIEDBERG ALBERTDirectorOct 03 '23Buy1.003,000,0003,000,0004,747,794Oct 05 04:30 PM
Zauderer MauricePresident and CEOOct 03 '23Buy1.00500,000500,000979,599Oct 05 04:31 PM
Zauderer MauricePresident and CEOOct 03 '23Buy0.935,0004,65017,116Oct 05 04:31 PM